1. Home
  2. MAIA vs LEE Comparison

MAIA vs LEE Comparison

Compare MAIA & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.36

Market Cap

79.0M

Sector

Health Care

ML Signal

N/A

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

N/A

Current Price

$7.37

Market Cap

173.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
MAIA
LEE
Founded
2018
1890
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
79.0M
173.8M
IPO Year
2022
2025

Fundamental Metrics

Financial Performance
Metric
MAIA
LEE
Price
$1.36
$7.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
448.6K
26.8K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
N/A
EPS
N/A
N/A
Revenue
N/A
$543,955,000.00
Revenue This Year
N/A
$5.48
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$3.34
52 Week High
$3.19
$11.88

Technical Indicators

Market Signals
Indicator
MAIA
LEE
Relative Strength Index (RSI) 49.02 38.23
Support Level $1.24 $7.14
Resistance Level $1.48 $8.79
Average True Range (ATR) 0.07 0.40
MACD 0.00 -0.07
Stochastic Oscillator 34.83 6.11

Price Performance

Historical Comparison
MAIA
LEE

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: